EU/3/18/1996

About

On 21 March 2018, orphan designation (EU/3/18/1996) was granted by the European Commission to Therapicon Srl, Italy, for melatonin for the treatment of neonatal encephalopathy.

Key facts

Active substance
melatonin
Disease / condition
Treatment of neonatal encephalopathy
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/1996

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Therapicon Srl
Via dei Grimani 10
20144 Milan
Italy
Tel. +39 02 433 042
E-mail: therapic@therapicon.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating